18 completed, 6 unknown. 24 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Completed 18, Unknown 6 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Leukemia, Erythroblastic, Acute: new trials by email Literature Review of Leukemia, Erythroblastic, Acute trials Research Report on Leukemia, Erythroblastic, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Daunorubicin, Cytarabine, Clofarabine - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 3 | Completed | ECOG-ACRIN Cancer Research Group | 727 | 2011-02-04 | 2024-12-13 |
| Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, daunorubicin, midostaurin - Leukemia | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 717 | 2008-04-01 | 2026-10-21 |
| Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia asparaginase, cytarabine, daunorubicin hydrochloride - Leukemia | Phase 3 | Completed | Children's Oncology Group | 1070 | 2006-08-01 | 2021-03-24 |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes alemtuzumab, arsenic trioxide, azacitidine - Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Completed | The University of New South Wales | 2000 | 2006-08-01 | 2013-08-26 |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission PR1 leukemia peptide vaccine, sargramostim, placebo - Leukemia | Phase 3 | Unknown | The Vaccine Company | 244 | 2005-05-01 | 2014-01-06 |
| Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia cytarabine, laromustine, placebo - Leukemia | Phase 3 | Completed | Vion Pharmaceuticals | 420 | 2005-03-01 | 2013-11-06 |
| Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes cytarabine, daunorubicin hydrochloride, gemtuzumab ozogamicin - Leukemia, Myelodysplastic Syndromes | Phase 3 | Completed | Stichting Hemato-Oncologie voor Volwassenen Nederland | 600 | 2005-01-01 | 2016-09-20 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Clinical Observation, Tipifarnib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 144 | 2004-08-18 | 2026-07-14 |
| S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML gemtuzumab ozogamicin, observation, Cytosine arabinoside - Leukemia | Phase 3 | Completed | SWOG Cancer Research Network | 637 | 2004-07-01 | 2015-09-30 |
| Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia gemtuzumab ozogamicin - Leukemia | Phase 2 / Phase 3 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 279 | 2004-06-01 | 2012-07-24 |
| Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia filgrastim, sargramostim, cytarabine - Leukemia, Myelodysplastic Syndromes | Phase 3 | Completed | Eastern Cooperative Oncology Group | 449 | 2002-09-17 | 2023-07-05 |
| Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia cytarabine, etoposide, gemtuzumab ozogamicin - Leukemia | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 472 | 2002-09-01 | 2012-08-27 |
| Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine - Leukemia, Myelocytic, Acute | Phase 3 | Completed | St. Jude Children's Research Hospital | 238 | 2002-08-01 | 2012-12-05 |
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, etoposide - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 720 | 2000-11-01 | 2013-06-04 |
| flt3L in Treating Patients With Acute Myeloid Leukemia recombinant flt3 ligand - Leukemia | Phase 3 | Completed | Eastern Cooperative Oncology Group | 2000-07-01 | 2013-06-24 | |
| Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia lintuzumab, cytarabine, etoposide - Leukemia | Phase 3 | Unknown | Facet Biotech | 2000-03-01 | 2013-11-06 | |
| Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia aldesleukin, filgrastim, busulfan - Leukemia | Phase 3 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 2000 | 1999-09-01 | 2009-12-23 |
| Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome cytarabine, daunorubicin hydrochloride, etoposide - Leukemia, Myelodysplastic Syndromes | Phase 3 | Completed | Leukemia Research Fund | 2000 | 1998-12-01 | 2013-12-18 |
| Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia filgrastim, cytarabine, daunorubicin hydrochloride - Leukemia, Myelodysplastic Syndromes | Phase 3 | Completed | Medical Research Council | 1998-08-01 | 2013-12-19 | |
| Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 3 | Completed | National Cancer Institute (NCI) | 640 | 1998-01-01 | 2013-06-04 |
Showing 20 of 24. Sign in to see all of them.
Leukemia, Myeloid, Acute (24) · Leukemia, Megakaryoblastic, Acute (23) · Leukemia, Monocytic, Acute (23) · Leukemia, Myelomonocytic, Acute (23) · Leukemia (19) · Congenital Abnormalities (16) · Leukemia, Basophilic, Acute (7) · Leukemia, Eosinophilic, Acute (7) · Anemia, Refractory, with Excess of Blasts (5) · Myelodysplastic Syndromes (5) · Leukemia, Promyelocytic, Acute (3) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Myeloproliferative Disorders (2)
Bone Marrow Diseases (24) · Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Leukemia, Myeloid (24) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Myeloproliferative Disorders (22) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Anemia (5) · Anemia, Refractory (5) · Leukemia (5) · Agranulocytosis (2) · Chronic Disease (2) · Cytopenia (2) · Disease Attributes (2)
Cytarabine (20) · Daunorubicin (15) · Etoposide (13) · Filgrastim (8) · Mitoxantrone (8) · Gemtuzumab (7) · Idarubicin (6) · Peripheral Blood Stem Cell Transplantation (6) · Cyclophosphamide (5) · Busulfan (4) · Observation (4) · Radiotherapy (4) · Tretinoin (3) · aldesleukin (3) · valspodar (3)
European Organisation for Research and Treatment of Cancer - EORTC (5) · National Cancer Institute (NCI) (3) · Eastern Cooperative Oncology Group (2) · Medical Research Council (2) · Alliance for Clinical Trials in Oncology (1) · Children's Oncology Group (1) · ECOG-ACRIN Cancer Research Group (1) · Facet Biotech (1) · Leukemia Research Fund (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · St. Jude Children's Research Hospital (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · The University of New South Wales (1) · The Vaccine Company (1)
United States (14) · United Kingdom (7) · Belgium (5) · Canada (5) · Netherlands (5) · France (4) · Germany (4) · Italy (4) · Israel (3) · Austria (2) · Portugal (2) · Australia (1) · Croatia (1) · Czechia (1) · Greece (1)
Alan K. Burnett, MD, FRCP (3) · Roel Willemze, MD, PhD (2) · Sergio Amadori, MD (2) · Alan S. Gamis, MD, MPH (1) · Bonny L. Johnson, RN, MSN (1) · Craig S. Rosenfeld, MD (1) · D. W. Milligan, MD (1) · Daniel Levitt, MD, PhD (1) · Franco Mandelli, MD (1) · Giovanna Meloni, MD (1) · Giuliana Alimena (1) · Jacob M. Rowe, MD (1) · James Foran (1) · Jeffrey Rubnitz, M.D., PhD (1) · John E. Godwin, MD, MS (1)
PMID 31375516, PMID 36184192, PMID 29926156, PMID 30523055, PMID 37267439, PMID 15761020, PMID 16484584, PMID 16932345, PMID 17315155, PMID 17339189, PMID 19291085, PMID 19710500, PMID 19826132, PMID 20038732, PMID 20451454, PMID 20522709, PMID 20716770, PMID 22627678, PMID 23471307, PMID 23538338, PMID 23591789, PMID 24127442, PMID 24297940, PMID 24383844, PMID 24986689, PMID 25092781, PMID 25527568, PMID 26811524, PMID 27133823, PMID 28644114, PMID 28883080, PMID 30382485, PMID 31171508, PMID 31645648, PMID 33049054, PMID 33080007, PMID 34162404, PMID 34596937, PMID 36815378, PMID 37185873, PMID 37534515, PMID 38295280, PMID 40294366, PMID 41890705, PMID 42085603
U10CA021115 (3), U10CA031946 (2), R01CA113482 (1), U10CA032102 (1), U10CA180820 (1)